Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene Autoleucel in Severe Active GPA or MPA
NCT06868290Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 8
01
Overview
Phase 2, randomised, single-blind trial of rapcabtagene autoleucel in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by Novartis. Primary endpoint: Event-free survival. Started Mar 2025; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT06868290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868290.